Better Therapeutics, Inc. (BTTX)
$1.3
Rating:
Recommendation:
-
| Symbol | BTTX |
|---|---|
| Price | $1.3 |
| Beta | 0.030 |
| Volume Avg. | 0.03M |
| Market Cap | 30.868M |
| Shares () | - |
| 52 Week Range | 0.912-5.1 |
| 1y Target Est | - |
| DCF Unlevered | BTTX DCF -> | |
|---|---|---|
| DCF Levered | BTTX LDCF -> | |
| ROE | -274.50% | Strong Sell |
| ROA | -217.52% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 289.15% | Strong Buy |
| P/E | - | |
| P/B | 4.25 | Strong Buy |
Latest BTTX news
About
Download (Excel)Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.